Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
CURE Pharmaceutical, an innovative drug delivery and development company, signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.
Researchers said Evidence is weak for whether medicinal cannabis treatments can relieve mental illnesses such as anxiety, depression and psychosis, and doctors should prescribe them with great caution.
Columbia Care Inc. announced the initiation of a research study designed to optimize the use of the company’s precisely manufactured, pharmaceutical-quality medical cannabis products through the identification of genetic factors affecting their safety and efficacy.
